Miriam Tendler

Dr. Miriam Tendler


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Vaccine
Verified
Journal Article
Closed access
MSMarilia Santini-Oliveira
Marilia Santini-Oliveira
RCRhea N. Coler
Rhea N. Coler
JPJuçara Parra
Juçara Parra
VVValdilea Veloso
Valdilea Veloso
LJLakshmi Jayashankar
Lakshmi Jayashankar
MTMiriam Tendler
Miriam Tendler

1 November 2008 in Acta Tropica
Verified
Journal Article
Closed access
MTMiriam Tendler
Miriam Tendler
ASAndrew J.G. Simpson
Andrew J.G. Simpson

12 May 2015 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MTMiriam Tendler
Miriam Tendler
MAMarilia Almeida
Marilia Almeida
ASAndrew Simpson
Andrew Simpson
Data herein reported and discussed refer to vaccination with the recombinant Fatty Acid Binding protein family member of the Schistosomes, called Sm14, discovered and developed under a Brazilian platform leaded by the Oswaldo Cruz Foundation, from the Health Ministry in Brazil, undertaken to assess safety and immunogenicity in healthy volunteers. This paper reviews past and recent outcomes of developmental phases of the Sm14 based anti Schistosomiasis vaccine addressed to, ultimately, impact transmission of the second most prevalent parasitic endemic disease worldwide.

1 June 2004 in Infection and Immunity
Verified
Journal Article
Open access
PDF file
PVPaula B. Varaldo
Paula B. Varaldo
LLLuciana C. C. Leite
Luciana C. C. Leite
WDWaldely O. Dias
Waldely O. Dias
EMEliane Miyaji
Eliane Miyaji
FTFabio I. G. Torres
Fabio I. G. Torres
DMDouglas McIntosh
Douglas McIntosh
The Sm14 antigen ofSchistosoma mansoniwas cloned and expressed inMycobacterium bovisBCG as a fusion with theMycobacterium fortuitumβ-lactamase protein under the control of its promoter, pBlaF*; the protein was localized in the bacterial cell wall. The rBCG-Sm14 strain was shown to be relatively stable in cultured murine and bovine monocytes in terms of infectivity, bacterial persistence, and plasmid stability. The immunization of mice with rBCG-Sm14 showed no induction of anti-Sm14 antibodies; however, splenocytes of immunized mice released increased levels of gamma interferon upon stimulation with recombinant Sm14 (rSm14), indicating an induction of a Th1-predominant cellular response against Sm14. Mice immunized with one or two doses of rBCG-Sm14 and challenged with liveS. mansonicercaria showed a 48% reduction in worm burden, which was comparable to that obtained by immunization with three doses of rSm14 purified fromEscherichia coli. The data presented here further enhance the status of Sm14 as a promising candidate antigen for the control of schistosomiasis and indicate that a one-dose regimen of rBCG-Sm14 could be considered a convenient means to overcome many of the practical problems associated with the successful implementation of a multiple-dose vaccine schedule in developing countries.

1 March 2003 in Parasite Immunology
Verified
Journal Article
Closed access
PDF file
MAMarília S. Almeida
Marília S. Almeida
HTHumberto Torloni
Humberto Torloni
PLPaulo Lee‐Ho
Paulo Lee‐Ho
MVMonica M. Vilar
Monica M. Vilar
NTNilton Thaumaturgo
Nilton Thaumaturgo
MTMiriam Tendler
Miriam Tendler

1 September 2001 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
PDF file
CRCelso Raul Romero Ramos
Celso Raul Romero Ramos
MVMônica Magno Vilar
Mônica Magno Vilar
Ana NascimentoAna Nascimento
Ana Nascimento
PHPaulo Lee Ho
Paulo Lee Ho
NTNilton Thaumaturgo
Nilton Thaumaturgo
MTMiriam Tendler
Miriam Tendler
Previous studies carried out with Sm14 in experimental vaccination against Schistosoma mansoni or Fasciola hepatica infections were performed with recombinant Sm14 (rSm14) produced in Escherichia coli by the pGEMEX system (Promega). The rSm14 was expressed as a 40 kDa fusion protein with the major bacteriophage T7 capsid protein. Vaccination experiments with this rSm14 in animal models resulted in consistent high protective activity against S. mansoni cercariae challenge and enabled rSm14 to be included among the vaccine antigens endorsed by the World Health Organization for phase I/II clinical trials. Since the preparation of pGEMEX based rSm14 is time consuming and results in low yield for large scale production, we have tested other E. coli expression systems which would be more suitable for scale up and downstream processing. We expressed two different 6XHis-tagged Sm14 fusion proteins in a T7 promoter based plasmids. The 6XHis-tag fusions allowed rapid purification of the recombinant proteins through a Ni+2-charged resin. The resulted recombinant 18 and 16 kDa proteins were recognized by anti-Sm14 antibodies and also by antiserum against adult S. mansoni soluble secreted/excreted proteins in Western-Blot. Both proteins were also protective against S. mansoni cercariae infection to the same extent as the rSm14 expressed by the pGEMEX system.